SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,490.00    40.00 (0.90%)
Bid:
4,400.00
Ask:
4,580.00
Spread: 180.00 (4.091%)
Market Cap: £299.07m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Trading Statement

18 Jul 2013 07:00

RNS Number : 5740J
Judges Scientific PLC
18 July 2013
 

 

 

Judges Scientific plc

Trading Statement

 

18 July 2013

 

Judges Scientific plc ('Judges Scientific', the 'Company' or the 'Group')

 

Trading Update

 

The Directors of Judges Scientific, the parent company of a group specialising in the design, manufacture and sale of scientific instruments, are pleased to update shareholders and the market with regard to the Group's trading performance during the first half of the current financial year.

The interim Income Statement for the six months to 30 June 2013 will not include any results from Scientifica Ltd ("Scientifica"), which was acquired on 26 June 2013 and represents the Group's largest acquisition to date. The interim Balance Sheet will reflect the acquisition.

The Group's businesses delivered a satisfactory trading performance during the period. The interim results, scheduled to be announced in September, are expected to show revenue growth of 14% compared with the six months to 30 June 2012; this includes organic growth of 4.4% and the effect of a full six-month contribution from Global Digital Systems ("GDS") and KE Developments ("KED") compared with a four-month contribution in the first half of 2012. The Board anticipates that interim profits before exceptional items will reflect this satisfactory sales performance. Adjusted basic earnings per share are also expected to advance, despite the 20% dilution resulting from the May 2012 share issue and the conversion of most of the convertible redeemable shares in the second half of 2012.

Order intake during the six-month period showed only slight organic growth, with a strong first quarter being followed by a weak second quarter. Had GDS and Scientifica been part of Judges throughout the first-half periods of both 2012 and 2013, the Group as presently constituted would have shown 13% growth in order intake for the period. The order book at 30 June 2013 (excluding Scientifica) represented 10.6 weeks of sales, somewhat ahead of the 10-week level at 30 June 2012.

Operating cash flow was healthy during the period. The interim Balance Sheet will show the impact of the Scientifica acquisition and of the majority of the building cost of the Stonecross property; net debt still rests at a prudent multiple of operating profit.

Several other companies in our sector have recently reported challenging conditions and our own markets have not been uniformly positive. However, the resilience of Judges' diversified business activities has enabled the Company to continue to pursue its objectives in a lacklustre environment.

 

 

For further information please contact:

Judges Scientific Plc

David Cicurel, CEO

Tel: 01342 323 600

 

Shore Capital (Nominated Adviser & Broker)

Pascal Keane

Edward Mansfield

Tel: 020 7408 4090

 

Cardew Group (Financial Public Relations)

Melvyn Marckus

Tel: 020 7930 0777 or 07775 896 491

 

Websites:

Judges Scientific: www.judges.uk.com 

Scientifica: http: www.scientifica.uk.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDMGMNVNNGFZM
Date   Source Headline
11th Jun 20264:34 pmRNSDirector/PDMR Shareholding
1st Jun 20262:24 pmRNSTotal Voting Rights
26th May 20265:18 pmRNSPurchase of Ordinary Shares
20th May 20262:52 pmRNSResult of AGM
11th May 20263:10 pmRNSDirector/PDMR Shareholding
8th May 20265:05 pmRNSDirector/PDMR Shareholding
28th Apr 20267:00 amRNSNotice of AGM
22nd Apr 202611:53 amRNSConfirmation of Full Year Results
9th Apr 202611:14 amRNSDirector/PDMR Shareholding
2nd Apr 20267:00 amRNSDirector/PDMR Shareholding
31st Mar 20267:00 amRNSUnaudited Preliminary Results
25th Mar 20267:00 amRNSNotice of Investor Presentation
10th Mar 20267:00 amRNSDirector/PDMR Shareholding
9th Feb 20261:49 pmRNSDirector/PDMR Shareholding
2nd Feb 20269:38 amRNSTotal Voting Rights
29th Jan 20263:31 pmRNSDirector/PDMR Shareholding
29th Jan 20267:00 amRNSGrant of Options
22nd Jan 20267:00 amRNSFull Year Trading Statement and Notice of Results
8th Jan 202611:18 amRNSDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSBlocklisting Return
22nd Dec 20257:00 amRNSBlocklisting Return
9th Dec 202510:25 amRNSDirector/PDMR Shareholding
3rd Dec 20257:00 amRNSAcquisition of the minority shareholding in GdB
26th Nov 20257:00 amRNSBoard Succession
13th Nov 20255:05 pmRNSDirector/PDMR Shareholding
11th Nov 202512:08 pmRNSDirector/PDMR Shareholding
3rd Nov 20257:00 amRNSTotal Voting Rights
20th Oct 20257:00 amRNSDirector/PDMR Shareholding
8th Oct 202511:43 amRNSDirector/PDMR Shareholding
1st Oct 202512:22 pmRNSTotal Voting Rights
18th Sep 20257:00 amRNSInterim Results
9th Sep 202511:42 amRNSDirector/PDMR Shareholding
21st Aug 20257:00 amRNSNotice of Investor Presentation
6th Aug 20255:46 pmRNSDirector/PDMR Shareholding
1st Aug 20257:00 amRNSTotal Voting Rights
30th Jul 20257:00 amRNSDirector/PDMR Shareholding
25th Jul 202510:07 amRNSDirector/PDMR Shareholding
24th Jul 20254:06 pmRNSDirector/PDMR Shareholding
24th Jul 20257:00 amRNSHalf Year Trading Update
8th Jul 20253:53 pmRNSDirector/PDMR Shareholding
1st Jul 20255:08 pmRNSTotal Voting Rights
1st Jul 20257:00 amRNSAppointment of Group Acquisitions Executive
23rd Jun 20257:00 amRNSBlocklisting Return
9th Jun 20251:37 pmRNSDirector/PDMR Shareholding
4th Jun 20255:03 pmRNSPurchase of Ordinary Shares
30th May 202512:06 pmRNSTotal Voting Rights
23rd May 202511:25 amRNSResult of AGM
13th May 20255:18 pmRNSPurchase of Ordinary Shares
8th May 20255:27 pmRNSDirector/PDMR Shareholding
28th Apr 20257:00 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.